MME and hydrops fetalis: ARNI, which consists of the neprilysin inhibitor sacubitril (AHU377) and the ARB valsartan (Tillman et al., 2019), is the first drug indicated to be superior to enalapril in reducing mortality for patients with HF and shows the potential to improve the left ventricular function of patients with HF (Solomon et al., 2016).